Evidence memo / Skin & pigmentation

Argireline (acetyl hexapeptide-8)

Also: acetyl hexapeptide-8 · acetyl hexapeptide-3 · AH8 · needle-free botox

The cosmetic peptide with the most real human data behind it, marketed as needle-free Botox on a mechanism that is genuinely botulinum-adjacent, and limited by the one thing the marketing never mentions: getting a hexapeptide through the stratum corneum.

Controlled human dataRandomized human dataInvestigational

The verdict

Our read at a glance.

Whether a peptide that interferes with neurotransmitter release in a dish does so after being rubbed on intact skin.

The signal
Unusually for a cosmetic ingredient, this has been tested in people. The original work described a synthetic hexapeptide with antiwrinkle activity, and several controlled studies since - including randomized and double-blind designs and work in Chinese subjects - report measurable reductions in wrinkle depth against vehicle. It has also been investigated for blepharospasm in registered clinical trials, which is a far more demanding endpoint than cosmetic appearance. A cosmetic-ingredient safety assessment of acetyl hexapeptide-8 amide has been published, and review work has looked specifically at the skin permeability question rather than assuming it.
The unknown
How much of the applied peptide reaches the neuromuscular junctions it is supposed to act on. Effect sizes in the cosmetic studies are modest, and the delivery literature exists precisely because penetration of a charged hexapeptide through intact stratum corneum is the weak link.
Our read
A rare cosmetic ingredient that genuinely has controlled human data, attached to a name that promises something it cannot deliver. The honest claim is a modest, measurable reduction in fine lines. The implied claim - that this is injectable neuromodulation in a jar - is not supported, and the delivery problem is the reason.

The mechanism

How it works.

Releasing a neurotransmitter requires the vesicle holding it to fuse with the nerve terminal membrane, and that fusion is carried out by the SNARE complex, a bundle of proteins including SNAP-25, syntaxin and VAMP. Botulinum toxin works by cleaving SNAP-25 outright, so the complex cannot assemble and the muscle cannot be told to contract. Argireline is a six-amino-acid fragment mimicking the N-terminal end of SNAP-25, and it competes for a place in the complex, destabilising assembly rather than destroying the protein. Less efficient vesicle fusion means less acetylcholine released, less muscle contraction, and softer expression lines. The mechanism is real, and it is also reversible, partial and competitive rather than enzymatic - which is one reason the effect is smaller. The other reason is arithmetic: botulinum toxin is injected into the muscle, while this has to cross the stratum corneum, a barrier specifically evolved to keep water-soluble molecules of exactly this size out.

Safety & regulatory boundary

The consequential part.

A cosmetic ingredient rather than an approved drug, so claims about appearance are permitted while claims to treat a condition are not. Safety at cosmetic concentrations appears good and reactions are mostly local irritation. It is not botulinum toxin and does not produce comparable muscle relaxation; treating the two as substitutes overstates it by an order of magnitude.

What's next

What we're watching.

The blepharospasm trials, which would be the first real functional endpoint, and delivery-system work that could change the penetration picture.

Context

Why this is discussed.

It is in a very large share of anti-ageing serums, it is cheap, and the needle-free Botox framing sets an expectation against the most effective cosmetic injectable there is.

The evidence base

16 cited references.

Regulatory & labels1

DailyMed label: Instant Anti Aging Wrinkle Eye Treatment Syringe

Guangzhou Meijiao Medical Biotechnology Co., Ltd. (FDA label) · 2025

Registered trials4

Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin

ClinicalTrials.gov · NA · COMPLETED · 2016-01

Acetyl Hexapeptide-8 for Blepharospasm

ClinicalTrials.gov · PHASE2 · TERMINATED · 2012-11

A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

ClinicalTrials.gov · PHASE1/PHASE2 · COMPLETED · 2009-07

Argireline in Treatment of Periorbital Wrinkles

ClinicalTrials.gov · PHASE3 · COMPLETED · 2009-03

Keep reading

Related published memos.